TimesSquare Capital Management LLC Purchases 58,760 Shares of Merus (NASDAQ:MRUS)

TimesSquare Capital Management LLC boosted its position in Merus (NASDAQ:MRUS) by 21.6% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 331,195 shares of the biotechnology company’s stock after purchasing an additional 58,760 shares during the period. TimesSquare Capital Management LLC owned about 0.48% of Merus worth $13,927,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Merus by 17.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 84,200 shares of the biotechnology company’s stock worth $4,207,000 after purchasing an additional 12,212 shares in the last quarter. GSA Capital Partners LLP bought a new stake in Merus in the 3rd quarter worth about $675,000. State of New Jersey Common Pension Fund D bought a new stake in Merus in the 3rd quarter worth about $1,870,000. US Bancorp DE bought a new stake in Merus in the 3rd quarter worth about $103,000. Finally, HighTower Advisors LLC bought a new stake in Merus in the 3rd quarter worth about $358,000. 96.14% of the stock is owned by institutional investors.

Merus Price Performance

NASDAQ MRUS opened at $45.07 on Thursday. Merus has a 1 year low of $37.77 and a 1 year high of $61.61. The stock has a market capitalization of $3.09 billion, a PE ratio of -11.41 and a beta of 1.11. The company’s 50 day simple moving average is $41.51 and its two-hundred day simple moving average is $46.96.

Wall Street Analysts Forecast Growth

MRUS has been the topic of a number of research analyst reports. Piper Sandler initiated coverage on shares of Merus in a research note on Thursday, February 13th. They issued an “overweight” rating and a $84.00 target price on the stock. The Goldman Sachs Group initiated coverage on shares of Merus in a research note on Thursday, November 21st. They issued a “buy” rating and a $73.00 target price on the stock. Wells Fargo & Company initiated coverage on shares of Merus in a research note on Friday, February 7th. They issued an “overweight” rating and a $91.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $85.00 target price on shares of Merus in a research note on Monday, December 2nd. Finally, Citigroup boosted their target price on shares of Merus from $89.00 to $97.00 and gave the company a “buy” rating in a research note on Monday, December 9th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $85.92.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.